A detailed history of Creative Planning transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Creative Planning holds 11,300 shares of ZNTL stock, worth $36,499. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,300
Previous 13,399 15.67%
Holding current value
$36,499
Previous $54,000 24.07%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 11, 2024

SELL
$2.9 - $4.57 $6,087 - $9,592
-2,099 Reduced 15.67%
11,300 $41,000
Q2 2024

Aug 15, 2024

BUY
$4.09 - $16.13 $7,398 - $29,179
1,809 Added 15.61%
13,399 $54,000
Q1 2024

May 10, 2024

BUY
$10.83 - $16.49 $6,389 - $9,729
590 Added 5.36%
11,590 $182,000
Q4 2023

Feb 14, 2024

BUY
$9.84 - $20.13 $108,240 - $221,430
11,000 New
11,000 $166,000

Others Institutions Holding ZNTL

About Zentalis Pharmaceuticals, Inc.


  • Ticker ZNTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,983,600
  • Market Cap $184M
  • Description
  • Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...
More about ZNTL
Track This Portfolio

Track Creative Planning Portfolio

Follow Creative Planning and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

News

Stay updated on Creative Planning with notifications on news.